Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that...
- Mechanism
- Curator reviewed · 2 references
Descartes-30 expresses a unique combination of DNases in patients and delivers a targeted treatment directly to the site of disease which eliminates neutrophil extracellular traps which are a key driver of inflammation and clotting in acute respiratory distress syndrome. This cell therapy is currently being investigated against COVID-19.
- Code names
- Descartes-30
Resolves to
What you can answer from here — as of April 23, 2025
Which companies are running trials of Descartes-30, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account